Copyright
©The Author(s) 2015.
World J Immunol. Nov 27, 2015; 5(3): 86-94
Published online Nov 27, 2015. doi: 10.5411/wji.v5.i3.86
Published online Nov 27, 2015. doi: 10.5411/wji.v5.i3.86
Table 2 Clinical trials of chimeric antigen receptor T-cell immunotherapy of haematological malignancy
| Target | No. of trials | Diseases |
| CD19 | 40 | Acute and chronic B-cell malignancies |
| Hodgkin’s lymphoma | ||
| CD30 | 4 | Hodgkin’s lymphoma; CD30+ non-Hodgkin’s lymphoma |
| CD20 | 2 | B-cell malignancy |
| CD22 | 1 | B-cell malignancy |
| Kappa light chain | 1 | B-cell malignancy |
| Multiple myeloma | ||
| CD33 | 1 | Acute myeloid leukaemia |
| CD138 | 1 | Multiple myeloma |
| CD123 | 1 | Acute myeloid leukaemia |
| Lewis Y antigen | Acute myeloid leukaemia Myelodysplastic syndrome; | |
| Multiple myeloma | ||
| NKG2D stress ligands | 1 | Acute myeloid leukaemia; Myelodysplastic syndrome; |
| Multiple myeloma | ||
| Combinatorial | 1 | CD16-containing "universal CAR" targeted with rituximab for B-cell malignancy |
- Citation: Schalkwyk MCV, Maher J. Chimeric antigen receptors: On the road to realising their full potential. World J Immunol 2015; 5(3): 86-94
- URL: https://www.wjgnet.com/2219-2824/full/v5/i3/86.htm
- DOI: https://dx.doi.org/10.5411/wji.v5.i3.86